Scholar Rock Holding CORP 8-K filings

Scholar Rock Holding Corporation's stockholders approved amendments to the company's charter, including increasing authorized shares and limiting officer liability, at their annual meeting on June 27, 2024.

Scholar Rock presented new preclinical data showing SRK-439, a myostatin inhibitor, preserves lean mass and attenuates fat rebound after GLP-1 receptor agonist withdrawal, and has dosed the first participants in a Phase 2 trial for apitegromab in obesity.

Scholar Rock presented encouraging Phase 1 trial data for SRK-181 in combination with pembrolizumab, showing anti-tumor activity in multiple cancer types, particularly in patients resistant to anti-PD-(L)1 therapies.

Scholar Rock initiates a Phase 2 trial for apitegromab in obesity and presents promising preclinical data for SRK-439, highlighting its potential in preserving lean muscle mass.

Scholar Rock has extended its lease agreement for its Cambridge headquarters by two years, with an option for a further five-year extension.

Scholar Rock announced its first quarter 2024 financial results, highlighted by progress in its SMA and cardiometabolic programs, and a cash runway extending into the second half of 2025.

Scholar Rock announced its full year 2023 financial results and provided updates on its clinical programs, including the Phase 3 SAPPHIRE trial for spinal muscular atrophy and a new Phase 2 trial for obesity.

Scholar Rock appoints Katie Peng to its Board of Directors and promotes Mo Qatanani to Chief Scientific Officer, signaling a focus on commercialization and research advancement.